Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. Shares of Structure Therapeutics (GPCR -0.30%) shot up more than 50% during the first week of June. The stock market is responding to a positive readout for an experimental weight-management drug the company is working on. Structure Therapeutics is a clinical-stage drugmaker developing an orally available therapy, called GSBR-1290. Structure's lead candidate works like semaglutide, the ...

About Structure Therapeutics Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities and BMO Capital Markets acted as joint book-running managers for the offering. Investors: Danielle Keatley Structure Therapeutics Inc. ir@structuretx.com Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on June 5, 2024. Copies of the registration statements can be accessed through the SEC's web ...

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters' option to purchase up to 1,360,045 addition ...

SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offer ...

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small mol ...

Qiming has maintained a steady investment pace in 2023 and continued to evaluate and invest in exciting and disruptive areas. Additionally, Qiming strategically participated follow-on investments in high-quality portfolio companies. SHANGHAI, June 4, 2024 /PRNewswire/ -- The 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing Partner at Qiming Venture Partners, has become a Forbes Midas Lister for the sixth consecutive ...

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000 American depositary shares (ADSs), each representing three ordinary shares. Structur ...

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000 American depositary shares (ADSs), each representing three ordinary shares. Structur ...

Structure Therapeutics (NASDAQ:GPCR) stock is surging today, up 60% after the biotech company reported promising results of its mid-stage trials for its weight loss pills. Indeed, after 12 weeks, patients on the treatment lost an average of 6.2% of their weight, with one-third of patients losing more than 10% of their weight. This is comparable to Eli Lilly (NYSE:LLY) oforglipron pill at roughly the same point of its study. However, this came at the cost of vomiting, which almost 66% of Structure's patients ...

GSBR-1290 Overview - GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, targeting type 2 diabetes mellitus (T2DM) and obesity [1] - Designed as a biased GPCR agonist, selectively activating the G-protein signaling pathway [1] - Phase 2a study completed in participants with obesity or overweight and T2DM with BMI ≥27 [1] - Phase 2b study in obesity expected to start in Q4 2024, with Phase 2 development plan in T2DM to be determined in H2 2024 [1] - Next-generation combination GLP-1R candidates are also in development, including GIP, amylin, glucagon, and apelin oral small molecules [1] Clinical Trial Results - GSBR-1290 achieved a placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK study at 12 weeks [3][7] - 67% of GSBR-1290-treated participants achieved ≥6% weight loss, and 33% achieved ≥10% weight loss at Week 12, compared to 0% for placebo [7] - The tablet formulation demonstrated comparable exposure to the capsule formulation, supporting dose proportional exposure and once-daily dosing [7] - GSBR-1290 showed generally favorable safety and tolerability, with low AE-related study discontinuations (5% in Phase 2a and 11% in PK study) [7] Future Development Plans - Phase 2b obesity study expected to begin in Q4 2024, using the tablet formulation and including approximately 300 participants [8] - IND submission to the FDA planned for Q3 2024 to support trials in chronic weight management [8] - The company anticipates using the tablet formulation for future studies, starting with the Phase 2b obesity study [10] Market and Industry Context - By 2030, the global prevalence of obesity is expected to reach 1 billion, highlighting the need for oral treatments that are scalable, stable, and cost-effective [6] - GSBR-1290 has the potential to become a best-in-class oral small molecule GLP-1RA and an ideal backbone for future combination therapeutics for obesity and related diseases [6] Company Background - Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule treatments for metabolic and cardiopulmonary conditions [11] - The company utilizes a structure-based drug discovery platform to develop GPCR-targeted therapies, aiming to overcome the limitations of traditional biologic and peptide therapies [11]